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Background. Shedding of Salmonella Typhi or Paratyphi in the stool or urine leads to contamination of food or water, which 
is a prerequisite for transmission of enteric fever. Currently, there are limited data on the effect of vaccination or prior exposure on 
stool shedding.
Methods. Six Salmonella Typhi or Paratyphi human challenge studies were conducted between 2011 and 2017. Participants were 
either unvaccinated or vaccinated with 1 of 4 vaccines: Vi-polysaccharide (Vi-PS), Vi-tetanus-toxoid conjugate vaccine (Vi-TT), live 
oral Ty21a vaccine, or an experimental vaccine (M01ZH09). Daily stool cultures were collected for 14 days after challenge.
Results. There were 4934 stool samples collected from 430 volunteers. Participants who received Vi-PS or Vi-TT shed less than 
unvaccinated participants (odds ratio [OR], 0.34; 95% confidence interval [CI], 0.15–0.77; P = .010 and OR, 0.41; 95% CI, 0.19–0.91, 
P = .029 for Vi-PS and Vi-TT, respectively). Higher anti-Vi immunoglobulin G titers were associated with less shedding of S. Typhi 
(P <  .0001). A nonsignificant reduction in shedding was associated with Ty21a vaccine (OR, 0.57; 95% CI, 0.27–1.20; P =  .140). 
Individuals previously exposed to S. Typhi shed less than previously unexposed individuals (OR, 0.30; 95% CI, 0.1–0.8; P = .016). 
Shedding of S. Typhi was more common than S. Paratyphi.
Conclusions. Prior vaccination with Vi vaccines, or natural infection, reduces onward transmission of S. Typhi. Field trials of 
Vi-TT should be designed to detect indirect protection, reflecting the consequence of reduced stool shedding observed in the human 
challenge model.
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Infection with Salmonella enterica subspecies enterica serovars 
Typhi or Paratyphi (S. Typhi or S. Paratyphi) is estimated to be 
responsible for between 11.6 and 26.9 million cases of enteric 
fever and 75 000–216 510 deaths annually [1–5]. Transmission 
of S. Typhi and S. Paratyphi occurs primarily through consump-
tion of contaminated food or water, via short-cycle or long- 
cycle transmission. Short-cycle transmission is defined as the 
contamination of food and water in the immediate environment, 
whereas long-cycle transmission is defined as contamination of 
the broader environment, such as pollution of water supplies by 
sewage or inadequate treatment of piped water [6]. The relative 
contribution of each transmission mode may vary depending 
on the epidemiological context and may differ between S. Typhi 
and S. Paratyphi [7]. As these serovars are human restricted, 
all modes of transmission involve shedding of the organism by 
infected individuals during incubation, acute disease, or conva-
lescence or by chronic long-term carriers, ultimately resulting in 
contamination of food or water consumed by susceptible indi-
viduals. Disease control is therefore likely to require the inte-
gration of initiatives to improve water quality, sanitation, and 
hygiene, coupled with the deployment of effective vaccines [8].
Vaccines that both protect against clinical disease as well as 
reduce shedding would likely have enhanced effectiveness by 
interrupting transmission and providing indirect protection 
to unvaccinated individuals. Live attenuated oral typhoid vac-
cine, Ty21a, reduced stool shedding in the early Maryland chal-
lenge studies [9] and appears to induce herd immunity in field 
trials [10]. However, there are conflicting data on the indirect 
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protection conferred by Vi-polysaccharide vaccines (Vi-PS) [11, 
12] and limited data on the impact of new Vi-tetanus-toxoid 
conjugate vaccines (Vi-TT) on stool shedding [13]. Finally, the 
impact of previous exposure to typhoidal Salmonella on stool 
shedding after subsequent exposure has not been previously 
explored.
Experimental challenge studies of closely monitored volun-
teers can be used to describe microbial dynamics in clinical and 
subclinical typhoid and paratyphoid infections, including the 
timing and pattern of stool shedding after challenge in naive 
or vaccinated individuals [14]. Early experimental human 
challenge studies in Maryland indicate that shedding is more 
common in individuals who develop typhoid disease. However, 
individuals who fail to develop disease following challenge can 
continue to shed bacteria for several weeks [15]. Differences 
in stool shedding patterns between S. Typhi and S. Paratyphi 
A are poorly understood. Improved estimates of stool shedding 
dynamics in enteric fever are needed, particularly in the context 
of different immune states, as these form important variables 
in models of typhoid transmission dynamics and estimates of 
vaccine impact [16, 17].
We performed an analysis of stool shedding dynamics in 
healthy volunteers enrolled into closely monitored S. Typhi 
and S. Paratyphi human challenge studies. Our aims in this 
study were to model stool shedding after experimental chal-
lenge and to compare those challenged with S. Typhi vs S. 
Paratyphi, participants who did or did not develop enteric 
fever after challenge, those who received typhoid vaccines 
vs those who were unvaccinated, rechallenged individuals 
previously exposed to S. Typhi or S. Paratyphi vs previously 
unexposed individuals, differences according to demographic 
variables, and the relationship between antibody levels and 
stool shedding.
METHODS
Typhoid and Paratyphoid Human Challenge Studies
Data were available from 6 enteric fever human challenge 
studies conducted in Oxford between 2011 and 2017. A list of 
included studies is provided in Table 1.
All challenge studies followed comparable protocols, detailed 
elsewhere (Supplementary Materials) [13, 18, 19, 20, 21, 22]. 
Briefly, healthy adults drank 120  mL of sodium bicarbonate 
solution prior to challenge. After challenge, daily blood and 
stool cultures were collected for 14 days. Participants were diag-
nosed with enteric fever if they had fever of 38oC for ≥12 hours 
and/or S. (Para)Typhi bacteremia detected ≥72 hours from 
challenge. Antibiotics were initiated at the time of diagnosis or 
at day 14 for those not diagnosed. All participants were effec-
tively treated, and no chronic carriers were identified.
Typhoid challenge was performed using the Qualies strain 
(genotype 3.1.0) [15, 23]. Paratyphoid challenge was performed 
using the S. Paratyphi A NVGH308 strain [14]
Stool Culture
Stool cultures were performed according to local proce-
dures based on national guidance at Oxford University 
Hospital National Health Service (NHS) Foundation Trust 
(Supplementary Materials) [24].
Table 1. List of Included Studies
Study Challenge Agent Study Type Vaccine Description References
1 OVG2009/10
(T1)
Salmonella Typhi 
Quailes strain
Observational … Dose-finding study
Low dose: 1–5 × 103 CFU (n = 20)
High dose: 1–5 × 104 CFU (n = 20)
 [18]
2 OVG2011/02
NCT01405521
(T2)
S. Typhi Quailes strain Vaccine RCT M01ZH09 (n = 31)a
Ty21a (n = 30)a
Placebo (n = 30)
Ty21a (3 dose) or M01ZH09 (single dose) 
vaccines compared with control
Challenge dose 1–5 × 104 CFU 28 days 
after vaccination
 [19]
3 OVG2013/07
NCT02100397
(P1)
S. Paratyphi 
A NVGH308 strain
Observational … Dose-finding study
High dose: 1–5 × 103 CFU (n = 20)
Low dose: 0.5–1 × 103 CFU (n = 20)
 [14]
4 OVG2014/08
NCT02324751
(VAST)
S. Typhi Quailes strain Vaccine RCT Vi-PS (n = 35)a
Vi-TT conjugate 
(n = 37)a
Placebo (n = 31)
Single dose Vi-PS (Typhim Vi®, Sanofi 
Pasteur) or Vi-TT (TypbarTCV®, Bharat 
Biotech) vaccines compared with 
control MenACWY
Challenge dose 1–5 × 104 CFU 28 days 
after vaccination
 [13]
5 OVG2014/01
NCT02192008
(PATCH)
S. Paratyphi 
A NVGH308 strain
S. Typhi Quailes strain
RCT … Naive challenge (S. Typhi and S. Paratyphi) vs 
rechallenge (homotypic and heterotypic)
S. Typhi challenge dose 1–5 × 104 CFU
S. Paratyphi challenge dose 1–5 × 103 CFU
 [20]
6 OVG2016/03
NCT03067961
(TYGER)
S. Typhi Quailes strain and
S. Typhi SB6000 (TT 
deficient)
RCT … Wild-type S. Typhi Quailes strain (n = 20)
SB6000 TT negative strain (n = 20)
Challenge dose 1–5 × 104 CFU
 [21]
Abbreviations: CFU, colony-forming unit; PS, polysaccharide; RCT, randomized controlled trial: TT, tetanus-toxoid.
aVaccinated and completed challenge.
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Antibody Measures
Anti-Vi immunoglobulin (Ig) G titers were measured using a 
commercial enzyme-linked immunosorbent assay (ELISA) kit 
(VaccZyme, The Binding Site, Birmingham, UK) according to the 
manufacturer’s guidelines [13]. IgG and IgA isotype responses 
to S. Typhi lipopolysaccharide (LPS) (Sigma L2387), S. Typhi 
Hd (University of Maryland 01-CVD0150622-01), S. Paratyphi 
A O:2 (GSK Vaccines for Global Health) [25], and S. Paratyphi 
Ha (University of Maryland CVD 1902D lot CVD141113-01) 
antigens were measured with an in-house ELISA in serum sam-
ples collected immediately prior to challenge [14, 18, 19].
Statistical Analyses
Stool culture data were combined in mixed effects logistic 
regression models, which included participant-specific ran-
dom intercepts to account for the multiple samples per person. 
Models were adjusted for the vaccine received, study, and, where 
applicable, challenge dose (high or low). “Day” was included in 
the model as a categorical factor to allow the odds of stool shed-
ding to vary by day.
An overall interaction term (day-by-vaccine) was tested to 
determine if vaccination altered the pattern of shedding over time. 
An interaction term for day-by-diagnosis status was used to com-
pare the pattern of shedding in those who were diagnosed with 
enteric fever and those who remained undiagnosed at day 14.
The linear predictor from the model was exported for each 
participant for each day and converted into a probability by tak-
ing the inverse logit. These probabilities are presented in figures 
with a loess smooth to illustrate the findings from the logistic 
regression models. Odds ratios (ORs) presented from logistic 
regression models represent the ratio of the odds of shedding in 
comparative groups on average across all 14 days.
All models were fitted in SAS version 9.4, and code is dis-
played in the Supplementary Materials.
RESULTS
In total, 4934 stool samples from 430 participants were ana-
lyzed; 3698 samples were from S. Typhi challenge partici-
pants and 1236 samples were from S. Paratyphi challenge 
participants (Table  2). In total, 14.5% of stool samples 
from S. Typhi-challenged participants were positive com-
pared with 7.5% of samples from those challenged with S. 
Paratyphi A.
Differences in S. Typhi Stool Shedding According to Diagnosis Status
There were 331 participants challenged with S. Typhi, of whom 
186 (56.2%) met the diagnostic criteria for typhoid fever [18]. 
The highest incidence of shedding was observed on day 1 and 
day 2 after challenge. The pattern of shedding over time was 
significantly different between those diagnosed and those who 
did not develop enteric fever (P < .0001 day-by-diagnosis inter-
action). The odds of shedding 1 day after challenge were 2.5 
times greater in those who were later diagnosed than in those 
who remained undiagnosed (OR, 2.49; 95% confidence inter-
val [CI], 1.32–4.69; P  =  .0049). On day 2 odds were 9 times 
higher in those later diagnosed (OR, 8.93; 95% CI, 3.86–20.61; 
P < .0001) and on day 3 were 23 times higher (OR, 22.59; 95% 
CI, 6.83–74.7; P < .0001). In the second week after challenge, 
many diagnosed participants had commenced antibiotics, and 
shedding ceased. In the undiagnosed participants, increased 
shedding was observed from day 10 onward, until those 
participants also received treatment on day 14 (Figure  1A). 
A  similar pattern was observed in historic challenge studies 
(Supplementary Figure S1).
Differences in Stool Shedding After S. Typhi or S. Paratyphi Challenge in 
Unvaccinated Participants
There were 197 unvaccinated participants exposed to S. Typhi 
and 109 unvaccinated participants exposed to S. Paratyphi. 
Table 2. Stool Microbiology by Challenge Agent and Study
Study
Number of 
Participants
Number of 
Participants With ≥1 
Positive Stool Sample
Number of Days Shedding
(Median [Interquartile 
Range])
Number of Samples 
from Salmonella Typhi-
challenged Participants
Number of Samples 
from Salmonella 
Paratyphi A-challenged 
Participants
TotalNegative Positive Negative Positive
1 OVG2009/10
(T1)
40 22 (55%) 1 [0–2] 520 54 (9%) ... ... 574
2 OVG2011/02
(T2)
92 72 (78%) 2 [1–4] 908 217 (19%) ... ... 1125
3 OVG2013/07
(P1)
40 17 (43%) 0 [0–1] ... ... 510 36 (7%) 546
4 OVG2014/08
(VAST)
103 64 (62%) 1 [0–2] 842 126 (13%) ... ... 968
5 OVG2014/01
(PATCH)
115 56 (45%) 0 [0–2] 562 84 (13%) 633 57 (8%) 1336
6 OVG2016/03
(TYGER)
40 24 (60%) 1 [0–2] 329 56 (15%) ... … 385
Total 430 255 (59%) 3161 537 (14.5%) 1143 93 (7.5%) 4934
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The odds of shedding in participants exposed to S. Typhi were 
twice as high as in those exposed to S. Paratyphi (OR, 1.97; 
95% CI, 1.00–3.88; P = .049). A sensitivity analysis excluding 
low-dose challenge gave a very similar estimate (OR, 1.97; 
P = .044). The dose received was nonsignificant in the model 
(Figure 1B).
Effect of Vaccination on Stool Shedding After S. Typhi Challenge
Data from 5 S. Typhi studies were analyzed. Participants chal-
lenged with a low dose or a genetically modified S. Typhi were 
excluded [21].
Participants who received Vi-PS or Vi-TT vaccine had lower 
rates of shedding than unvaccinated participants (OR, 0.34; 
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Figure 1. Probability of bacterial shedding in stool by day in controlled human infection enteric fever studies. (A) N = 331 participants challenged with Salmonella Typhi 
according to diagnosis status. Nondiagnosed N = 145, diagnosed N = 186. (B) Unvaccinated participants exposed to oral challenge with S. Typhi (N = 197) or S. Paratyphi 
(N = 109) bacteria. (C) Vaccinated and unvaccinated participants challenged with 1–5 × 104 colony-forming units S. Typhi wild-type bacteria according to vaccine received. 
Control vaccine or no vaccine (N = 158); M01ZH09, experimental typhoid vaccine (N = 32); Ty21a, live attenuated oral typhoid vaccine (N = 30); Vi-PS, Vi-polysaccharide typhoid 
vaccine (Typhim Vi®, Sanofi Pasteur; N = 35); Vi-TT, Vi-tetanus toxoid conjugate vaccine (TypbarTCV®, Bharat Biotech; N = 37)
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95% CI, 0.15–0.77; P = .010 and OR, 0.41; 95% CI, 0.19–0.91; 
P  =  .029 for Vi-PS and Vi-TT, respectively). In Ty21a vac-
cine recipients, there was a nonsignificant reduction in shed-
ding compared with unvaccinated controls (OR, 0.57; 95% 
CI, 0.27–1.20; P  =  .14; Figure  1C). There were no differences 
between unvaccinated participants and those who received the 
M01ZH09 vaccine or between any other groups after adjusting 
for study-specific variation. The vaccine-by-day interaction 
term was nonsignificant, showing that the pattern of shedding 
over time was similar for all vaccines even though the amount 
of shedding differed.
Effect of Previous Exposures
Participants previously exposed to S. Typhi had less stool 
shedding than previously unexposed individuals (T-T 
vs T,  OR, 0.33; 95% CI, 0.1–0.8; P  =  .016; Figure  2). For 
those participants who received S. Typhi challenge, previ-
ous exposure to S. Paratyphi significantly increased stool 
shedding compared with previous S. Typhi exposure (P-T 
vs T-T: OR, 7.5; 95% CI, 2.0–28.4; P  =  .003) and nonsig-
nificantly increased the rate of bacterial shedding com-
pared with previously unexposed individuals (P-T vs T: 
OR, 2.5; 95% CI, 0.8–8.0; P  =  .125). For those receiving 
S. Paratyphi challenge, there were no differences between 
groups, and a lower rate of shedding in general was observed 
in comparison with those exposed to S. Typhi challenge.
Variation in Shedding According to Age and Sex
In 197 unvaccinated participants (34% female), the median 
number of samples provided was 11 (interquartile range [IQR], 
8–14) for women and 12 (IQR, 9–15) for men. Men had propor-
tionately more positive stool samples than women (OR, 1.78; 
95% CI, 1.10–2.87; P = .0187). Age was not significantly related 
to shedding (P = .795).
Antibody Levels Prior to Challenge
Higher anti-Vi IgG antibody titers prior to challenge were asso-
ciated with less bacterial shedding after challenge with S. Typhi 
(P < .0001). There was no relationship between anti-LPS IgG or 
anti-Hd IgG and shedding after challenge with either S. Typhi or 
S. Paratyphi (Figure 3). IgA and IgM responses to S. Typhi LPS 
and Hd antigens were nonsignificant (Supplementary Figure S2).
DISCUSSION
Shedding of S. Typhi and S. Paratyphi bacilli is a prerequisite 
for onward transmission in these human-restricted infections. 
This is the first comprehensive analysis of bacterial shedding 
from almost 5000 stool samples taken after deliberate chal-
lenge of healthy volunteers with S. Typhi or S. Paratyphi. We 
demonstrate that stool shedding is more common in individu-
als who meet the case definition of enteric fever (fever 38oC for 
≥12 hours and/or S. (Para)Typhi bacteremia), but shedding can 
also occur in the absence of bacteremia or clinical symptoms of 
disease. Vaccination with Vi-PS or Vi-TT significantly reduced 
stool shedding of S. Typhi following controlled human infection, 
suggesting that these vaccines are likely to reduce onward trans-
mission of disease. The decreased shedding following vaccina-
tion with the live-attenuated Ty21a vaccine was not significant, 
possibly due to the small sample sizes available for these com-
parisons and moderate protective efficacy of Ty21a in the chal-
lenge model. In earlier challenge studies with Ty21a involving 
larger numbers of participants who received a freshly harvested 
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Figure 2. Bacterial shedding in stool after S. Typhi or S. Paratyphi challenge, according to previous exposure. P = S. Paratyphi naive (n = 39); P-P = S. Paratyphi rechallenge 
after previous S. Paratyphi exposure (n = 13); P-T = S. Typhi challenge after previous S. Paratyphi exposure (n = 10); T = S. Typhi challenge in S. Typhi naive participants (n = 71); 
T-P = S. Paratyphi challenge after previous S. Typhi exposure (n = 27); T-T = S. Typhi rechallenge after previous S. Typhi exposure (n = 27). See Supplementary Table S1 for 
model outputs.
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formulation of vaccine, shedding of S. Typhi was significantly 
reduced in recipients of the live oral vaccine [9].
The effects of Vi-PS or Vi-TT vaccination on indirect protec-
tion and stool shedding are poorly understood. A cluster ran-
domized control trial in Kolkata, India, demonstrated that Vi-PS 
vaccination can result in indirect protection against typhoid 
fever in unvaccinated individuals resident in population clusters 
randomized to Vi-PS vaccine [11]. However, indirect protection 
of Vi-PS was not observed in another cluster randomized trial 
conducted in Karachi, Pakistan. One difference is that the trial in 
Kolkata vaccinated adults as well as children [12].
The reduction in stool shedding observed in individuals vac-
cinated with a Vi-TT conjugate vaccine is an important find-
ing. To date, there are no completed cluster randomized trials 
of typhoid conjugate vaccines. However, 1 trial is ongoing in 
Bangladesh, and individually randomized trials are ongoing in 
Nepal and Malawi [26]. A previous Vi-conjugate vaccine with 
Pseudomonas aeruginosa exotoxin A  as a carrier protein was 
shown to have a high vaccine  efficacy (VE)  in Vietnam (VE, 
91.1%; 95% CI, 78.6%–96.5%) [27]. Vi-TT vaccine is highly 
immunogenic in children [28], with demonstrated efficacy of 
54.6%–87.1% in a controlled human infection model (depend-
ing on the diagnostic criteria used) [13] and vaccine efficacy 
of 85% estimated from serological data [29]. In October 2017 
the World Health Organization recommended the introduction 
of typhoid conjugate vaccines for children aged >6 months in 
typhoid-endemic countries [8]. It remains to be determined to 
what degree the reduction in shedding associated with Vi-TT 
vaccination will translate to indirect protection of unvaccinated 
persons in field studies. If the reduction in shedding translates 
to indirect protection of nonvaccinees in field settings, the over-
all effectiveness of Vi-TT conjugate vaccines could be signifi-
cantly higher than is estimated in challenge studies.
Current models that predict the potential impact of 
Vi-conjugate vaccines account for this potential indirect pro-
tection by assuming that transmission of S. Typhi is reduced 
in a manner that is proportional to the vaccine efficacy (ie, by 
preventing infection and hence shedding among a proportion 
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Figure 3. Relationship between days of bacterial shedding in stool after Salmonella Typhi or S. Paratyphi challenge and antibody levels prior to challenge. (A) Anti-Vi 
immunoglobulin (Ig) G prior to challenge with S. Typhi. (B) Anti-Hd IgG prior to challenge with S. Typhi. (C) Anti-O:2 IgG prior to challenge with S. Paratyphi. (D) Anti-S. Typhi 
lipopolysaccharide IgG prior to challenge with S. Typhi. Days: y-axis represents the predicted total number of days of stool shedding (out of 14). The total number of days 
was determined from the logistic regression model by summing across all 14 days the predicted probability for each day for each person. Abbreviation: Ig, immunoglobulin.
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of vaccinated individuals). The results presented here support 
such assumptions. The protection afforded by Vi-TT against 
typhoid infection is similar to its effect against stool shedding. 
When both are expressed as ORs, the effects of Vi-TT against 
typhoid diagnosis and shedding have largely overlapping CIs 
(typhoid diagnosis: OR, 0.16; 95% CI, 0.05–0.46 and shedding: 
OR, 0.41; 95% CI, 0.19–0.91). However, more analysis is needed 
to examine the relationships between vaccination, stool shed-
ding, and the development of clinical typhoid and how this may 
vary between the human challenge model and field settings. 
Additionally, the mechanism by which anti-Vi antibodies pre-
vent stool shedding requires further investigation.
The nonsignificant reductions in shedding with Ty21a vac-
cine contrast with data from early challenge studies, where 
Ty21a was associated with a reduction in any stool shedding of 
S. Typhi from between day 4 and day 30 post-challenge (OR, 
0.08; 95% CI, 0.02–0.29) [9]. The differences may result from 
methodological differences between the Oxford and Maryland 
challenge studies, including mode of administration, pretreat-
ment with sodium bicarbonate instead of milk, differences in 
challenge dose (Maryland, 105 organisms; Oxford, 104), and 
criteria for initiating antibiotics. Of note, Ty21a appeared to 
provide herd immunity in field studies conducted in Chile [10].
As was observed in early typhoid challenge studies, early 
shedding increased the likelihood of subsequent development 
of typhoid fever [15]. Interestingly, we observed an increase in 
shedding in the undiagnosed group from day 10 onward. It is 
possible that late shedding represents a harbinger of subsequent 
bacteremia or fever, such that a proportion of the “undiagnosed” 
group may have developed enteric fever had the infection not 
been halted by commencing antibiotics at day 14. Conversely, 
late, asymptomatic shedding has been described in undiagnosed 
participants from early challenge studies, where shedding peaked 
in the second week post-challenge before clearing spontaneously 
by 6 weeks (in the absence of clinical disease or antibiotic treat-
ment) [15]. These data emphasize that a proportion of individ-
uals exposed to typhoidal Salmonella will act as asymptomatic 
short-term carriers who transiently shed in the absence of overt 
clinical disease; this is a factor that should be considered when 
determining the target population for vaccination campaigns.
In individuals previously challenged with S. Typhi, we 
detected a significant reduction in the rate of stool shedding 
compared with naive controls. A  single episode of typhoid 
exposure is thought to confer moderate protection against sub-
sequent clinical disease (estimated at approximately 23% from 
historical challenge studies [30]), and modeling studies assume 
that multiple episodes of typhoid exposure are required to 
induce functional immunity [31]. These are the first data to sug-
gest that prior typhoid exposure significantly affects the pattern 
of shedding following rechallenge, albeit from a small sample 
size (n = 27 rechallenged). Interestingly, we observed that indi-
viduals previously exposed to S. Paratyphi A had substantially 
higher rates of shedding when rechallenged with S. Typhi. The 
reasons for the increased risk of typhoid shedding on hetero-
typic rechallenge are unclear and are the subject of ongoing 
studies focusing on the role of secretory IgA [32].
When shedding rates were compared between typhoid and 
paratyphoid challenge studies, rates of shedding following S. 
Typhi challenge were twice as high as those following S. Paratyphi 
A challenge. The higher rate of shedding following typhoid chal-
lenge may reflect the higher challenge dose administered in the 
typhoid model (104 vs 103 colony-forming units), or differences 
may exist between these serovars in host–pathogen interactions 
and transmission mechanisms. Several studies in areas coendemic 
for S. Typhi and S. Paratyphi A have suggested that transmission 
dynamics and risk factors may differ between the 2 serovars [7, 
33, 34]. For example, S. Paratyphi A cases appear to be more spa-
tially dispersed than S. Typhi cases in an urban area [33] and may 
be particularly associated with foodborne transmission [7, 34]. 
Improved understanding of paratyphoid shedding and transmis-
sion dynamics will be an important consideration in the develop-
ment of vaccines for paratyphoid fever [35].
There are several limitations to assessing stool shedding using 
data from human challenge studies. The population enrolled 
comprises adults from a nonendemic country; shedding 
dynamics may differ in individuals from endemic countries 
with prior immune priming or in children, who represent the 
majority of enteric fever cases (but not necessarily the majority 
of shedders). In this analysis, data were pooled across 6 studies 
conducted over 6  years. While all samples were processed in 
the same laboratory using consistent protocols, study-to-study 
variation may still exist in the sensitivity of stool testing; thus, 
“study” was adjusted for in all models. Furthermore, challenge 
was conducted using only a single strain of S. Typhi (Quailes) or 
S. Paratyphi A (NVGH308) at a single dose, which may not mir-
ror the shedding dynamics of contemporary circulating strains 
in Asia and Africa, such as the multidrug-resistant associated 
H58 (genotype 4.3.1) strain of S. Typhi [36]. These limitations 
primarily reflect safety considerations required for controlled 
human challenge, and these data should be interpreted along-
side emerging data from surveillance studies [37].
In summary, we have performed the first detailed model of shed-
ding dynamics in the context of controlled typhoid and paratyphoid 
challenge and provide evidence for efficacy of new and existing 
typhoid vaccines (Vi-PS and Vi-TT) in reducing rates of shedding. 
These studies illustrate the value of closely monitored experimen-
tal human challenge studies in obtaining novel insights into host–
pathogen interactions and microbial dynamics, which can directly 
inform the disease control efforts for priority pathogens.
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